Avalide advisory committee
Executive Summary
FDA's Cardio-Renal Drugs Advisory Committee will meet April 18 to review an sNDA for Bristol-Myers Squibb's antihypertensive agent Avalide. Bristol is seeking approval for first-line use of Avalide, a combination of Bristol's angiotensin II receptor blocker Avapro and the diuretic hydrochlorothiazide, in hypertensive patients unlikely to achieve blood pressure goals on one drug. The committee will be asked to consider what constitutes adequate data to support such a claim and how the information can be most usefully displayed in the labeling. Avalide was approved by FDA in August 1998 (1"The Pink Sheet" May 17, 1999, p. 25). The meeting will be held at the CDER advisory committee conference room, 5630 Fishers Lane, Rockville, Md., beginning at 8 a.m...
You may also be interested in...
Bristol-Myers Squibb/Sanofi Avalide
Average wholesale price for 150 mg irbesartan/12.5 mg hydrochlorothiazide tablets will be $1.51. AWP for the 300 mg irbesartan/12.5 mg hydrochlorothiazide tablets will be $1.57. The companies began shipping the product in early May. Avalide, a combination of the companies' angiotensin II receptor blocker Avapro and the diruretic hydrochlorothiazide, was approved by FDA in August 1998
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.